Form 8-K - Current report:
SEC Accession No. 0001610618-25-000002
Filing Date
2025-01-07
Accepted
2025-01-07 17:12:13
Documents
15
Period of Report
2025-01-03
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CIDARA THERAPEUTICS, INC. FORM 8-K cdtx-20250103.htm   iXBRL 8-K 33334
2 SEPARATION AGREEMENT exhibit1012025-01x07.htm EX-10.1 137653
3 AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY exhibit9912025-01x07.htm EX-99.1 16850
  Complete submission text file 0001610618-25-000002.txt   349770

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cdtx-20250103.xsd EX-101.SCH 1780
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cdtx-20250103_lab.xml EX-101.LAB 22804
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cdtx-20250103_pre.xml EX-101.PRE 13048
17 EXTRACTED XBRL INSTANCE DOCUMENT cdtx-20250103_htm.xml XML 2829
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Filer) CIK: 0001610618 (see all company filings)

EIN.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36912 | Film No.: 25515687
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)